Signaling from p53 to NF-κB determines the chemotherapy responsiveness of neuroblastoma

Neoplasia

Volumn 8, Issue 11, 2006, Pages 967-977

  Armstrong, Michael B ^a   Bian, Xin ^a   Liu, Yihong ^a   Subramanian, Chitra ^a   Ratanaproeksa, Anthony B ^a   Shao, Feng ^a   Yu, Victor C ^b   Kwok, Roland P S ^a   Opipari Jr , Anthony W ^a   Castle, Valerie P ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Chemotherapy; H Ras; Neuroblastoma; NF B; p53

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CYCLOHEXIMIDE; DOXORUBICIN; ETOPOSIDE; GGTI 287; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN P53; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NEUROBLASTOMA; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

EID: 33750686594     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06574     Document Type: Article

References (56)

1. Frappaz D, Michon J, Coze C, Berger C, Plouvier E, Lasset C, Bernard JL, Stephan JL, Bouffet E, Buclon M, et al. (2000). LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 18, 468-476.
2. Biedler JL, Helson L, and Spengler BA (1973). Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 33, 2643-2652.
3. Biedler JL, Spengler BA, Chang TD, and Ross RA (1988). Transdifferentiation of human neuroblastoma cells results in coordinate loss of neuronal and malignant properties. Prog Clin Biol Res 271, 265-276.
4. Ciccarone V, Spengler BA, Meyers MB, Biedler JL, and Ross RA (1989). Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res 49, 219-225.
5. DeClerck YA, Bomann ET, Spengler BA, and Biedler JL (1987). Differential collagen biosynthesis by human neuroblastoma cell variants. Cancer Res 47, 6505-6510.
6. Rettig WJ, Spengler BA, Chesa PG, Old LJ, and Biedler JL (1987). Coordinate changes in neuronal phenotype and surface antigen expression in human neuroblastoma cell variants. Cancer Res 47, 1383-1389.
7. Ross RA and Biedler JL (1985). Presence and regulation of tyrosinase activity in human neuroblastoma cell variants in vitro. Cancer Res 45, 1628-1632.
8. Ross RA, John T, Reis D, Spengler BA, and Biedler JL (1980). Neurotransmitter-synthesizing enzymes in human neuroblastoma cells: relationship to morphological diversity, in Advances in Neuroblastoma Research, AE Evans, Editor. Raven Press: New York. pp. 151-160.
9. Ross RA, Spengler BA, and Biedler JL (1983). Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 71, 741-747.
10. Tumilowicz JJ, Nichols WW, Cholon JJ, and Greene AE (1970). Definition of a continuous human cell line derived from neuroblastoma. Cancer Res 30, 2110-2118.
11. Bian X, Opipari AW Jr, Ratanaproeksa AB, Boitano AE, Lucas PC, and Castle VP (2002). Constitutively active NFkappa B is required for the survival of S-type neuroblastoma. J Biol Chem 277, 42144-42150.
12. Bian X, McAllister-Lucas LM, Shao F, Schumacher KR, Feng Z, Porter AG, Castle VP, and Opipari AW Jr (2001). NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem 276, 48921-48929.
13. Karin M and Lin A (2002). NF-kappaB at the crossroads of life and death. Nat Immunol 3, 221-227.
14. Panet H, Barzilai A, Daily D, Melamed E, and Offen D (2001). Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. J Neurochem 77, 391-398.
15. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, and Schwaninger M (1999). NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat Med 5, 554-559.
16. Bohuslav J, Chen LF, Kwon H, Mu Y, and Greene WC (2004). p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem 279, 26115-26125.
17. Sherr CJ (2004). Principles of tumor suppression. Cell 116, 235-246.
18. Lowe SW, Ruley HE, Jacks T, and Housman DE (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967.
19. Wallace-Brodeur RR and Lowe SW (1999). Clinical implications of p53 mutations. Cell Mol Life Sci 55, 64-75.
20. Wu GS and Ding Z (2002). Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 21, 1-8.
21. Ryan KM, Ernst MK, Rice NR, and Vousden KH (2000). Role of NF-kappaB in p53-mediated programmed cell death. Nature 404, 892-897.
22. Ronca F, Chan SL, and Yu VC (1997). 1-(5-Isoquinolinesulfonyl)-2- methylpiperazine induces apoptosis in human neuroblastoma cells, SH-SY5Y, through a p53-dependent pathway. J Biol Chem 272, 4252-4260.
23. Schreiber E, Matthias P, Muller MM, and Schaffner W (1989). Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17, 6419.
24. Usami I, Kubota M, Bessho R, Kataoka A, Koishi S, Watanabe K, Sawada M, Lin YW, Akiyama Y, and Furusho K (1998). Role of protein tyrosine phosphorylation in etoposide-induced apoptosis and NF-kappa B activation. Biochem Pharmacol 55, 185-191.
25. Inohara N, Koseki T, Lin J, del Peso L, Lucas PC, Chen FF, Ogura Y, and Nunez G (2000). An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. J Biol Chem 275, 27823-27831.
26. Ghoda L, Lin X, and Greene WC (1997). The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. J Biol Chem 272, 21281-21288.
27. Di Bartolomeo S, Di Sano F, Piacentini M, and Spinedi A (2000). Apoptosis induced by doxorubicin in neurotumor cells is divorced from drug effects on ceramide accumulation and may involve cell cycle-dependent caspase activation. J Neurochem 75, 532-539.
28. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, and Howley PM (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136.
29. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, and Reynolds CP (2001). Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 61, 6185-6193.
30. Fang L, Li G, Liu G, Lee SW, and Aaronson SA (2001). p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. EMBO J 20, 1931-1939.
31. Ongusaha PP, Kim JI, Fang L, Wong TW, Yancopoulos GD, Aaronson SA, and Lee SW (2003). p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop. EMBO J 22, 1289-1301.
32. Finco TS and Baldwin AS Jr (1993). Kappa B site-dependent induction of gene expression by diverse inducers of nuclear factor kappa B requires Raf-1. J Biol Chem 268, 17676-17679.
33. Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, and Baldwin AS Jr (1997). Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem 272, 24113-24116.
34. Millan O, Ballester A, Castrillo A, Oliva JL, Traves PG, Rojas JM, and Bosca L (2003). H-Ras-specific activation of NF-kappaB protects NIH 3T3 cells against stimulus-dependent apoptosis. Oncogene 22, 477-483.
35. Kitanaka C, Kato K, Ijiri R, Sakurada K, Tomiyama A, Noguchi K, Nagashima Y, Nakagawara A, Momoi T, Toyoda Y, et al. (2002). Increased Ras expression and caspase-independent neuroblastoma cell death: possible mechanism of spontaneous neuroblastoma regression. J Natl Cancer Inst 94, 358-368.
36. Lerner EC, Qian Y, Hamilton AD, and Sebti SM (1995). Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 270, 26770-26773.
37. Ikeda H, Hirato J, Akami M, Suzuki N, Takahashi A, Kuroiwa M, and Matsuyama S (1996). Massive apoptosis detected by in situ DNA nick end labeling in neuroblastoma. Am J Surg Pathol 20, 649-655.
38. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, and Lunec J (2001). Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 61, 8-13.
39. Takita J, Hayashi Y, Nakajima T, Adachi J, Tanaka T, Yamaguchi N, Ogawa Y, Hanada R, Yamamoto K, and Yokota J (1998). The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients. Oncogene 17, 3137-3143.
40. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, and White PS (2001). Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res 61, 679-686.
41. Lewis TS, Shapiro PS, and Ahn NG (1998). Signal transduction through MAP kinase cascades. Adv Cancer Res 74, 49-139.
42. Chang L and Karin M (2001). Mammalian MAP kinase signalling cascades. Nature 410, 37-40.
43. Johnson GL and Lapadat R (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911-1912.
44. Seger R and Krebs EG (1995). The MAPK signaling cascade. FASEB J 9, 726-735.
45. Tibbles LA and Woodgett JR (1999). The stress-activated protein kinase pathways. Cell Mol Life Sci 55, 1230-1254.
46. Waskiewicz AJ and Cooper JA (1995). Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr Opin Cell Biol 7, 798-805.
47. Werlen G, Hausmann B, Naeher D, and Palmer E (2003). Signaling life and death in the thymus: timing is everything. Science 299, 1859-1863.
48. Tang D, Wu D, Hirao A, Lahti JM, Liu L, Mazza B, Kidd VJ, Mak TW, and Ingram AJ (2002). ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 277, 12710-12717.
49. Briant L, Robert-Hebmann V, Sivan V, Brunet A, Pouyssegur J, and Devaux C (1998). Involvement of extracellular signal-regulated kinase module in HIV-mediated CD4 signals controlling activation of nuclear factor-kappa B and AP-1 transcription factors. J Immunol 160, 1875-1885.
50. Chen BC and Lin WW (2001). PKC- and ERK-dependent activation of I kappa B kinase by lipopolysaccharide in macrophages: enhancement by P2Y receptor-mediated CaMK activation. Br J Pharmacol 134, 1055-1065.
51. Dhawan P and Richmond A (2002). A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem 277, 7920-7928.
52. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, and McCubrey JA (2003). Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17, 1263-1293.
53. Rowinsky EK, Windle JJ, and Von Hoff DD (1999). Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17, 3631-3652.
54. Repasky GA, Chenette EJ, and Der CJ (2004). Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol 14, 639-647.
55. Shields JM, Pruitt K, McFall A, Shaub A, and Der CJ (2000). Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 10, 147-154.
56. Tanaka T, Slamon DJ, Shimada H, Shimoda H, Fujisawa T, Ida N, and Seeger RC (1991). A significant association of Ha-ras p21 in neuroblastoma cells with patient prognosis. A retrospective study of 103 cases. Cancer 68, 1296-1302.